Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (NASDAQ: PODD) is a Massachusetts-based medical device company known for its Omnipod tubeless insulin pump platform, which is designed to simplify life for people with diabetes. The Insulet news feed on Stock Titan aggregates company announcements, earnings updates, product milestones, and strategic disclosures that shape the PODD stock narrative and the evolution of automated insulin delivery.
Investors and observers can follow news on the Omnipod Insulin Management System and the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors to automate insulin dosing without multiple daily injections or fingersticks. Company releases highlight regulatory clearances, such as FDA 510(k) decisions for Omnipod 5 algorithm enhancements, as well as technology demonstrations at events like the Consumer Electronics Show, where Insulet presents its vision for “liveable technology” in connected health.
The PODD news stream also covers quarterly and annual financial results, long-range financial outlooks, and Investor Day presentations in which Insulet outlines its growth strategy in automated insulin delivery markets. Additional updates include sustainability initiatives like the expansion of the U.S. Pod recycling program, collaborations such as the Omnipod Mango color partnership with Pantone, and governance developments including executive and board appointments.
By reviewing Insulet news on this page, readers can track how the company’s Omnipod platform, innovation roadmap, financial performance, and corporate actions intersect. Bookmark this feed to monitor new product features, regulatory developments, strategic events, and other disclosures that may be relevant to understanding PODD as both a medical technology business and a publicly traded stock.
Insulet Corporation (NASDAQ: PODD) reported Q2 2021 revenues of $263.2 million, a 16.3% increase from the prior year. Omnipod revenue reached $242.1 million with a 19.9% increase. U.S. Omnipod revenue was $150.5 million (up 16.8%), while international revenue hit $91.6 million (up 25.1%). Despite a gross margin rise to 69.4%, the company reported a net loss of $25.0 million due to a debt extinguishment loss. Adjusted EBITDA improved to $52.3 million. Insulet reaffirms its 2021 revenue guidance of 16%-20% growth.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will present at two virtual investor conferences. The Canaccord 41st Annual Growth Conference is scheduled for August 11, 2021, at 11:00 a.m. ET, followed by the UBS Genomics 2.0 and MedTech Innovations Summit on August 12, 2021, at 4:00 p.m. ET. Live audio webcasts can be accessed via investors.insulet.com, with replays available post-event. Insulet is dedicated to enhancing diabetes management through its innovative Omnipod Insulin Management System.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will release its financial results for Q2 2021 on August 5, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time. The Omnipod Insulin Management System continues to innovate in diabetes management, providing up to three days of insulin delivery without the need for needles.
Insulet Corporation (NASDAQ: PODD) announced positive results from its pivotal trial for the Omnipod 5 Automated Insulin Delivery System, focusing on children aged 2 to 5.9 years with type 1 diabetes. The trial showed a reduction in HbA1c from 7.4% to 6.9% and increased time in range from 57.2% to 68.1%. Additionally, 100% of participants opted to continue using Omnipod 5 in a 12-month extension phase, indicating satisfaction. The results were shared at the American Diabetes Association's 81st Scientific Sessions.
Insulet Corporation (NASDAQ: PODD) announced its schedule for the American Diabetes Association's 81st Scientific Sessions from June 25-29, 2021, where it will present new clinical outcomes data on the Omnipod 5 Automated Insulin Delivery System. This includes findings from the pivotal trial for preschool children and results following transitions from multiple daily injections for patients aged 6 to 70. A total of eight presentations are planned. The Omnipod 5 has received breakthrough device designation from the FDA and is expected to launch in limited release in the latter half of 2021.
Insulet Corporation (NASDAQ: PODD) reported a strong financial performance for Q1 2021, with revenues of $252.3 million, marking a 27.4% increase from the previous year. Omnipod revenue contributed $233.2 million, up 22.9%. The gross margin improved to 66.4%, and operating income rose to $16.3 million. The company achieved a net loss of $0.0 million compared to a loss of $2.1 million in Q1 2020. Insulet is optimistic for 2021, raising revenue guidance to 16%-20%. They presented favorable data at ENDO 2021, indicating improved outcomes for users of the Omnipod 5 system.
Insulet Corporation (NASDAQ: PODD) will present at the virtual BofA Securities 2021 Health Care Conference on May 12, 2021, at 4:15 p.m. (ET). The company is a leader in tubeless insulin pump technology with its Omnipod® products, designed to enhance the lives of diabetes patients. Interested parties can listen to the presentation live via Insulet's investor page, where a replay will also be available afterward.
Insulet's innovative Omnipod system simplifies insulin delivery with a wearable, needle-free design, enhancing comfort for users.
Summary not available.
Insulet Corporation (NASDAQ:PODD) has priced a $500 million senior secured term loan B facility and a $60 million senior secured revolving facility. The term loan will be issued at 99.75% of the aggregate principal amount, bearing interest at LIBOR plus 3.25% with a 0.50% LIBOR floor. The revolving loan interest will range from LIBOR plus 2.75% to 3.25%, depending on the company's leverage ratio. Proceeds will be utilized for general corporate purposes, including retiring debt and funding investments. Closing is subject to customary conditions.
Insulet Corporation (NASDAQ:PODD) has announced the syndication of new senior secured credit facilities, which includes a revolving facility and a term loan B facility. The completion of these facilities will depend on lender commitments and market conditions. The proceeds from these credit facilities will be utilized for general corporate purposes, including debt retirement and funding investments. Morgan Stanley is leading the transaction as the arranger and active bookrunner.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
